<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02196467</url>
  </required_header>
  <id_info>
    <org_study_id>SIRUL 104501</org_study_id>
    <secondary_id>299825</secondary_id>
    <nct_id>NCT02196467</nct_id>
  </id_info>
  <brief_title>Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients</brief_title>
  <official_title>Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I/II of the clinical trial is to investigate whether the transplantation of normal&#xD;
      myoblasts throughout one muscle (the extensor carpi radialis) of the patients is safe and&#xD;
      will improve the strength of that muscle. During this Phase I/II, the patients will be&#xD;
      transplanted with myoblasts grown from the muscle biopsy of a donor and kept frozen in liquid&#xD;
      nitrogen. Thirty million myoblasts will be injected per cm cube in a progressively higher&#xD;
      surface of the radialis (i.e., 3, 6 and 9 cm2). The contralateral muscle will be injected&#xD;
      with saline to serve as a control. The strength of both muscles will be measured at 3 months&#xD;
      post transplantation to verify whether the myoblast transplantation improved the strength of&#xD;
      the muscle. If there is no significant strength improvement, the protocol will be terminated&#xD;
      immediately for that patient. If there is a significant strength improvement, the patient&#xD;
      will be maintained under immunosuppression until 6 months post transplant and his strength&#xD;
      will be re-evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duchenne Muscular Dystrophy (DMD) is a degenerative disease of genetic origin, due to a&#xD;
      mutation in the gene coding for the protein dystrophin. This mutation leads to deficiency of&#xD;
      dystrophin in the myofibers, causing progressive muscle degeneration by the following&#xD;
      mechanism: (1) dystrophin deficiency leads to myofibers being very vulnerable to muscle&#xD;
      contraction-relaxation, causing frequent damage and necrosis of myofibers; (2) necrosis is&#xD;
      followed by myofiber regeneration, as long as the regenerative capacity of muscle is not&#xD;
      exhausted; (3) when the regenerative capacity of the muscle is exhausted, myofibers become&#xD;
      atrophic and are ultimately lost; (4) fibrosis and fat infiltration replace the lost&#xD;
      myofibers. This progressive muscle destruction takes place in most muscles of the limbs and&#xD;
      trunk, leading to progressive loss of muscle strength, musculotendinous contractures,&#xD;
      restrictive respiratory insufficiency and premature death between 17 and 30 years.&#xD;
&#xD;
      The transplantation of myoblasts obtained from a healthy donor is a potential treatment of&#xD;
      DMD. Following intramuscular injection, donor myoblasts fuse with the myofibers of the&#xD;
      patient, introducing the normal dystrophin gene in them. In a previous Phase 1A clinical&#xD;
      trial, the investigators proved that transplantation of myoblasts grown from the muscle&#xD;
      biopsy of a healthy donor introduced the normal dystrophin gene in the DMD myofibers, with&#xD;
      the consequent expression of the normal dystrophin mRNA and restoration of the dystrophin&#xD;
      protein in several myofibers.&#xD;
&#xD;
      The aim of this Phase I/II of the clinical trial is to investigate whether the&#xD;
      transplantation of normal myoblasts throughout one muscle (in this case, the extensor carpi&#xD;
      radialis) of DMD patients is safe and will improve the strength of that muscle. The patients&#xD;
      will be transplanted with myoblasts grown from the muscle biopsy of a healthy donor. Thirty&#xD;
      million myoblasts will be injected per cm cube in a progressively higher volume of muscle&#xD;
      (i.e., 3, 6 and 9 cm cube). The contralateral muscle will be injected with saline as a&#xD;
      control. The patients and the investigators will be blind to the side injected with cells.&#xD;
      The strength of both muscles will be measured at 3 months post transplant to verify if&#xD;
      myoblast transplantation increased muscle strength. If there is no significant strength&#xD;
      increase, the protocol will be terminated immediately for that patient. If there is a&#xD;
      significant strength increase, the patient will be maintained under immunosuppression until 6&#xD;
      months and the muscle strength will be re-evaluated.&#xD;
&#xD;
      The objectives of this Phase I/II clinical trial with DMD patients are thus:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To evaluate the safety of a procedure of high-density injections of donor myoblasts&#xD;
      throughout a muscle (under immunosuppression by tacrolimus).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To evaluate whether myoblast transplantation resulted in the presence of&#xD;
           dystrophin-positive myofibers of donor origin.&#xD;
&#xD;
        2. To evaluate whether myoblast transplantation improved the muscle strength or prevent or&#xD;
           slowed down the progression of the muscle weakness as shown by the following parameters:&#xD;
&#xD;
           2.1) Increase of the voluntary strength of the subject's wrist extension done by the&#xD;
           extensor carpi radialis 12 or 24 weeks after myoblast transplantation compared with the&#xD;
           pre-transplant values of the same muscle.&#xD;
&#xD;
           2.2) Reduction of the fatigue of the voluntary strength of the subject's wrist extension&#xD;
           done by the extensor carpi radialis 12 or 24 weeks after myoblast transplantation&#xD;
           compared with the pre-transplant fatigue values of the same muscle.&#xD;
&#xD;
           2.3) Reduce the progression of the muscle weakness in the myoblast injected muscle&#xD;
           compared with the control contralateral muscle.&#xD;
&#xD;
        3. To verify the long term effectiveness of the tacrolimus immunosuppression to control&#xD;
           acute rejection in myoblast transplantation (by examining the presence of muscle fibers&#xD;
           expressing normal dystrophin and the absence of specific immune responses)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events as a measure of safety.</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The patients will be monitored for local and systemic potential adverse effects due to the transplantation and for adverse effects associated with immunosuppression with tacrolimus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of dystrophin-positive fibers in a muscle biopsy 3 or 6 months after myoblast transplantation.</measure>
    <time_frame>6 months after the myoblast transplantation</time_frame>
    <description>The presence of dystrophin positive fibers will be assessed in a muscle biopsy done 6 months after the myoblast transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strength of the Extensor carpi radialis muscles.</measure>
    <time_frame>At 3 and 6 months after myoblast transplantation.</time_frame>
    <description>The strength of both Extensor carpi radialis will be evaluated 3 and 6 months after the myoblast transplantation to evaluate whether this transplantation improved the muscle strength, prevented or slowed down the progression of the muscle weakness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of a cellular and humoral reaction against the donor antigens</measure>
    <time_frame>Every 4 weeks after transplantation for 6 months</time_frame>
    <description>To assess antibody-mediated immune responses, a blood sample will be obtained at days D-14 and D15, at week 4 and every 4 weeks until the end of the treatment schedule according to the transplant pattern of the subject, and at the 3 and 6 month follow ups. These blood samples will be used to make cross-matches to determine whether the subject is producing antibodies reacting with the donor myoblasts. The antibodies against donor myoblasts will be detected by flow cytometry. Antibodies against donor HLA class I and II antigens will also be assessed by flow cytometry using single HLA antigen-coated beads (Flow PRA beads, One Lambda, Canoga Park, CA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Myoblast transplantation &amp; strength</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearms, resuspended in saline. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline injection &amp; strength</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The same saline solution used in the previous arm, but without cells, will be injected similarly per centimeter cube in the Extensor carpi radialis of the contralateral patient's forearm. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Myoblast transplantation</intervention_name>
    <description>30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).</description>
    <arm_group_label>Myoblast transplantation &amp; strength</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Saline injection</intervention_name>
    <description>A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).</description>
    <arm_group_label>Saline injection &amp; strength</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical diagnosis of DMD must be confirmed (i.e., with supporting confirmation&#xD;
             demonstrated by the identification of a mutation in the dystrophin gene compatible&#xD;
             with DMD or presence of less than 10% dystrophin positive fibers in a muscle biopsy in&#xD;
             a subject with DMD).&#xD;
&#xD;
          -  The subject has to be older than 16 years of age.&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  If on corticosteroids, a stable dose must be maintained for 6 months prior to myoblast&#xD;
             transplantation and throughout the trial&#xD;
&#xD;
          -  A potential haplotype compatible donor (the father, the mother, a brother or sister&#xD;
             who is more than 18 years old) should be available.&#xD;
&#xD;
          -  The subject must be able to move both wrists, with an MRC scale score of greater than&#xD;
             or equal to 2.&#xD;
&#xD;
          -  Subject must have been vaccinated for pneumococcus and Haemophilus influenzae.&#xD;
&#xD;
          -  For subjects who are sexually active, willingness to abstain from sexual intercourse&#xD;
             or employ a barrier or medical method of contraception for the duration of the study.&#xD;
&#xD;
          -  For subjects that need assisted ventilation, a stable regimen of non-invasive&#xD;
             ventilation parameters for 3 months prior to the first myoblast transplantation and&#xD;
             anticipation that they will be on a stable regimen throughout the study.&#xD;
&#xD;
          -  Written informed consent of the subject and donor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An abnormal sensory examination&#xD;
&#xD;
          -  Persisting abnormal values in a hemogram (red blood cells, white blood cells,&#xD;
             hemoglobin or platelets out of laboratory normal range).&#xD;
&#xD;
          -  A history of chronic infection.&#xD;
&#xD;
          -  Abnormal glycosylated hemoglobin level and/or fasting blood glucose (values out of&#xD;
             laboratory normal range)&#xD;
&#xD;
          -  Previous neoplasia.&#xD;
&#xD;
          -  Previous tuberculosis or potential carrier of latent tuberculosis.&#xD;
&#xD;
          -  Any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic,&#xD;
             metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or&#xD;
             other major disease as determined by the Investigator that is not related to DMD&#xD;
&#xD;
          -  Previous history of renal problems or laboratory analyses suggestive of a renal&#xD;
             problem (cystatin C, blood urea nitrogen, electrolytes out of laboratory normal&#xD;
             range).&#xD;
&#xD;
          -  Previous biopsies or intramuscular injections in any of the extensor carpi radialis.&#xD;
&#xD;
          -  Subject who participated to phase 1A of myoblast transplantation&#xD;
&#xD;
          -  The subject uses a drug that is not compatible with tacrolimus (see section 6&#xD;
             &quot;Concomitant medications&quot; of protocol) within the last month. If the subject has&#xD;
             previously used one of these drugs, the washout period before the onset of tacrolimus&#xD;
             should be at least 1 month.&#xD;
&#xD;
          -  Subject tests positive for HIV-1, HIV-2, antigen HIV-1, HBC (hepatitis B surface&#xD;
             antigen (HBsAg) and hepatitis B core antigen) HCV, HTLV-1 and anti-HTLV-2.&#xD;
&#xD;
          -  The subject was submitted to electromyography in the extensor carpi radialis, within&#xD;
             the last 6 months.&#xD;
&#xD;
          -  There are pre-existing antibodies in the subject serum against the donor lymphocytes.&#xD;
&#xD;
          -  Any change (initiation, dose adjustment, interruption or discontinuation) in any&#xD;
             medication that may affect muscle function (eg. Losartan, coenzyme Q10, green tea&#xD;
             extract, idebenone, creatine, nutritional supplements, etc.) within 3 months of the&#xD;
             first myoblast transplantation.&#xD;
&#xD;
          -  Any change in cardiac medications (ACE inhibitor, beta-blocker, etc.) within 3 months&#xD;
             of first myoblast transplantation.&#xD;
&#xD;
          -  Any surgery or fracture of the upper extremity within 3 months prior to first myoblast&#xD;
             transplantation or plans to have surgery during the course of the trial.&#xD;
&#xD;
          -  No haplotype compatible donor is available.&#xD;
&#xD;
          -  Unwillingness or inability of the subject to understand and comply with the&#xD;
             requirements of this protocol in the opinion of the Investigator or sponsor.&#xD;
&#xD;
          -  Previous tuberculosis or potential carrier of latent tuberculosis.&#xD;
&#xD;
          -  Previous treatment with any other investigational product within 6 months of myoblast&#xD;
             transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Campbell, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jack Puymirat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du CHU de Quebec</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Campbell, MD MSc FRCPC</last_name>
    <phone>(519) 685-8332</phone>
    <email>craig.campbell@lhsc.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacques Tremblay, PhD</last_name>
    <phone>(418)-525-4444</phone>
    <phone_ext>47307</phone_ext>
    <email>Jacques-P.Tremblay@crchul.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du CHU de Quebec - CHUL</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Skuk D, Goulet M, Roy B, Piette V, Cote CH, Chapdelaine P, Hogrel JY, Paradis M, Bouchard JP, Sylvain M, Lachance JG, Tremblay JP. First test of a &quot;high-density injection&quot; protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord. 2007 Jan;17(1):38-46. doi: 10.1016/j.nmd.2006.10.003. Epub 2006 Dec 4.</citation>
    <PMID>17142039</PMID>
  </reference>
  <reference>
    <citation>Skuk D, Goulet M, Roy B, Chapdelaine P, Bouchard JP, Roy R, Dugre FJ, Sylvain M, Lachance JG, Deschenes L, Senay H, Tremblay JP. Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol. 2006 Apr;65(4):371-86. doi: 10.1097/01.jnen.0000218443.45782.81.</citation>
    <PMID>16691118</PMID>
  </reference>
  <reference>
    <citation>Skuk D, Vilquin JT, Tremblay JP. Experimental and therapeutic approaches to muscular dystrophies. Curr Opin Neurol. 2002 Oct;15(5):563-9. doi: 10.1097/00019052-200210000-00007.</citation>
    <PMID>12352000</PMID>
  </reference>
  <reference>
    <citation>Hogrel JY, Zagnoli F, Canal A, Fraysse B, Bouchard JP, Skuk D, Fardeau M, Tremblay JP. Assessment of a symptomatic Duchenne muscular dystrophy carrier 20 years after myoblast transplantation from her asymptomatic identical twin sister. Neuromuscul Disord. 2013 Jul;23(7):575-9. doi: 10.1016/j.nmd.2013.04.007. Epub 2013 May 31.</citation>
    <PMID>23731976</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>July 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2014</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myoblast</keyword>
  <keyword>transplantation</keyword>
  <keyword>strength</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The clinical trial results that have a relation to its objectives will be published as scientific papers in scientific journals or presented at scientific meetings, but without revealing the identity of the participants who will always remain anonymous.</ipd_description>
    <ipd_time_frame>The data will begin to be available as of the fall of 2019, not being decided yet for how long.</ipd_time_frame>
    <ipd_access_criteria>Information to be shared will be the expression of dystrophin, changes in strength, and evidence or not of rejection, in the muscles injected, as well as the side effects observed.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02196467
org study id: SIRUL 104501
secondary id: 299825
nct id: NCT02196467
lead sponsor: 
has dmc: Yes
This Phase I/II of the clinical trial is to investigate whether the transplantation of normal
      myoblasts throughout one muscle (the extensor carpi radialis) of the patients is safe and
      will improve the strength of that muscle. During this Phase I/II, the patients will be
      transplanted with myoblasts grown from the muscle biopsy of a donor and kept frozen in liquid
      nitrogen. Thirty million myoblasts will be injected per cm cube in a progressively higher
      surface of the radialis (i.e., 3, 6 and 9 cm2). The contralateral muscle will be injected
      with saline to serve as a control. The strength of both muscles will be measured at 3 months
      post transplantation to verify whether the myoblast transplantation improved the strength of
      the muscle. If there is no significant strength improvement, the protocol will be terminated
      immediately for that patient. If there is a significant strength improvement, the patient
      will be maintained under immunosuppression until 6 months post transplant and his strength
      will be re-evaluated.
Duchenne Muscular Dystrophy (DMD) is a degenerative disease of genetic origin, due to a
      mutation in the gene coding for the protein dystrophin. This mutation leads to deficiency of
      dystrophin in the myofibers, causing progressive muscle degeneration by the following
      mechanism: (1) dystrophin deficiency leads to myofibers being very vulnerable to muscle
      contraction-relaxation, causing frequent damage and necrosis of myofibers; (2) necrosis is
      followed by myofiber regeneration, as long as the regenerative capacity of muscle is not
      exhausted; (3) when the regenerative capacity of the muscle is exhausted, myofibers become
      atrophic and are ultimately lost; (4) fibrosis and fat infiltration replace the lost
      myofibers. This progressive muscle destruction takes place in most muscles of the limbs and
      trunk, leading to progressive loss of muscle strength, musculotendinous contractures,
      restrictive respiratory insufficiency and premature death between 17 and 30 years.

      The transplantation of myoblasts obtained from a healthy donor is a potential treatment of
      DMD. Following intramuscular injection, donor myoblasts fuse with the myofibers of the
      patient, introducing the normal dystrophin gene in them. In a previous Phase 1A clinical
      trial, the investigators proved that transplantation of myoblasts grown from the muscle
      biopsy of a healthy donor introduced the normal dystrophin gene in the DMD myofibers, with
      the consequent expression of the normal dystrophin mRNA and restoration of the dystrophin
      protein in several myofibers.

      The aim of this Phase I/II of the clinical trial is to investigate whether the
      transplantation of normal myoblasts throughout one muscle (in this case, the extensor carpi
      radialis) of DMD patients is safe and will improve the strength of that muscle. The patients
      will be transplanted with myoblasts grown from the muscle biopsy of a healthy donor. Thirty
      million myoblasts will be injected per cm cube in a progressively higher volume of muscle
      (i.e., 3, 6 and 9 cm cube). The contralateral muscle will be injected with saline as a
      control. The patients and the investigators will be blind to the side injected with cells.
      The strength of both muscles will be measured at 3 months post transplant to verify if
      myoblast transplantation increased muscle strength. If there is no significant strength
      increase, the protocol will be terminated immediately for that patient. If there is a
      significant strength increase, the patient will be maintained under immunosuppression until 6
      months and the muscle strength will be re-evaluated.

      The objectives of this Phase I/II clinical trial with DMD patients are thus:

      Primary objective:

      To evaluate the safety of a procedure of high-density injections of donor myoblasts
      throughout a muscle (under immunosuppression by tacrolimus).

      Secondary objectives:

        1. To evaluate whether myoblast transplantation resulted in the presence of
           dystrophin-positive myofibers of donor origin.

        2. To evaluate whether myoblast transplantation improved the muscle strength or prevent or
           slowed down the progression of the muscle weakness as shown by the following parameters:

           2.1) Increase of the voluntary strength of the subject's wrist extension done by the
           extensor carpi radialis 12 or 24 weeks after myoblast transplantation compared with the
           pre-transplant values of the same muscle.

           2.2) Reduction of the fatigue of the voluntary strength of the subject's wrist extension
           done by the extensor carpi radialis 12 or 24 weeks after myoblast transplantation
           compared with the pre-transplant fatigue values of the same muscle.

           2.3) Reduce the progression of the muscle weakness in the myoblast injected muscle
           compared with the control contralateral muscle.

        3. To verify the long term effectiveness of the tacrolimus immunosuppression to control
           acute rejection in myoblast transplantation (by examining the presence of muscle fibers
           expressing normal dystrophin and the absence of specific immune responses)
allocation: Randomized
intervention model: Single Group Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Number of Participants with Serious and Non-Serious Adverse Events as a measure of safety.
time frame: Up to 6 months
description: The patients will be monitored for local and systemic potential adverse effects due to the transplantation and for adverse effects associated with immunosuppression with tacrolimus.
measure: Percentage of dystrophin-positive fibers in a muscle biopsy 3 or 6 months after myoblast transplantation.
time frame: 6 months after the myoblast transplantation
description: The presence of dystrophin positive fibers will be assessed in a muscle biopsy done 6 months after the myoblast transplantation.
measure: Strength of the Extensor carpi radialis muscles.
time frame: At 3 and 6 months after myoblast transplantation.
description: The strength of both Extensor carpi radialis will be evaluated 3 and 6 months after the myoblast transplantation to evaluate whether this transplantation improved the muscle strength, prevented or slowed down the progression of the muscle weakness.
measure: Presence of a cellular and humoral reaction against the donor antigens
time frame: Every 4 weeks after transplantation for 6 months
description: To assess antibody-mediated immune responses, a blood sample will be obtained at days D-14 and D15, at week 4 and every 4 weeks until the end of the treatment schedule according to the transplant pattern of the subject, and at the 3 and 6 month follow ups. These blood samples will be used to make cross-matches to determine whether the subject is producing antibodies reacting with the donor myoblasts. The antibodies against donor myoblasts will be detected by flow cytometry. Antibodies against donor HLA class I and II antigens will also be assessed by flow cytometry using single HLA antigen-coated beads (Flow PRA beads, One Lambda, Canoga Park, CA).
arm group label: Myoblast transplantation & strength
arm group type: Experimental
description: 30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearms, resuspended in saline. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
arm group label: Saline injection & strength
arm group type: Sham Comparator
description: The same saline solution used in the previous arm, but without cells, will be injected similarly per centimeter cube in the Extensor carpi radialis of the contralateral patient's forearm. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
intervention type: Biological
intervention name: Myoblast transplantation
description: 30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
arm group label: Myoblast transplantation & strength
intervention type: Procedure
intervention name: Saline injection
description: A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
arm group label: Saline injection & strength
criteria: 
gender: Male
minimum age: 16 Years
maximum age: N/A
healthy volunteers: No
last name: Craig Campbell, MD MSc FRCPC
role: Principal Investigator
affiliation: University of Western Ontario, Canada
last name: Jack Puymirat, MD
role: Principal Investigator
affiliation: Centre de recherche du CHU de Quebec
last name: Craig Campbell, MD MSc FRCPC
phone: (519) 685-8332
email: craig.campbell@lhsc.on.ca
last name: Jacques Tremblay, PhD
phone: (418)-525-4444
phone ext: 47307
email: Jacques-P.Tremblay@crchul.ulaval.ca
facility: 
status: Recruiting
facility: 
status: Recruiting
country: Canada
citation: Skuk D, Goulet M, Roy B, Piette V, Cote CH, Chapdelaine P, Hogrel JY, Paradis M, Bouchard JP, Sylvain M, Lachance JG, Tremblay JP. First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord. 2007 Jan;17(1):38-46. doi: 10.1016/j.nmd.2006.10.003. Epub 2006 Dec 4.
PMID: 17142039
citation: Skuk D, Goulet M, Roy B, Chapdelaine P, Bouchard JP, Roy R, Dugre FJ, Sylvain M, Lachance JG, Deschenes L, Senay H, Tremblay JP. Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol. 2006 Apr;65(4):371-86. doi: 10.1097/01.jnen.0000218443.45782.81.
PMID: 16691118
citation: Skuk D, Vilquin JT, Tremblay JP. Experimental and therapeutic approaches to muscular dystrophies. Curr Opin Neurol. 2002 Oct;15(5):563-9. doi: 10.1097/00019052-200210000-00007.
PMID: 12352000
citation: Hogrel JY, Zagnoli F, Canal A, Fraysse B, Bouchard JP, Skuk D, Fardeau M, Tremblay JP. Assessment of a symptomatic Duchenne muscular dystrophy carrier 20 years after myoblast transplantation from her asymptomatic identical twin sister. Neuromuscul Disord. 2013 Jul;23(7):575-9. doi: 10.1016/j.nmd.2013.04.007. Epub 2013 May 31.
PMID: 23731976
responsible party type: Sponsor
mesh term: Muscular Dystrophies
mesh term: Muscular Dystrophy, Duchenne
sharing ipd: Yes
ipd description: The clinical trial results that have a relation to its objectives will be published as scientific papers in scientific journals or presented at scientific meetings, but without revealing the identity of the participants who will always remain anonymous.
ipd time frame: The data will begin to be available as of the fall of 2019, not being decided yet for how long.
ipd access criteria: Information to be shared will be the expression of dystrophin, changes in strength, and evidence or not of rejection, in the muscles injected, as well as the side effects observed.